AGP Executive Report
Last update: 10 hours agoObesity drug pipeline: Novo Nordisk agreed to pay up to US$2.6bn to license Hengrui Pharma’s investigational once-weekly oral GLP-1/GIP dual agonist (HRS-1596), with a US$300m upfront and milestones/royalties; the deal covers most markets but excludes mainland China, Hong Kong, Macao and Taiwan, while Hengrui prepares Phase 1 studies for weight management and type 2 diabetes. Muscle-loss protection in weight loss: Regeneron reported new Phase 2 COURAGE results showing trevogrumab can help prevent lean mass and muscle loss during GLP-1 (semaglutide)-induced weight loss, with further combo studies planned in older adults. Macao healthcare access: Macao Union Medical Center outlined National Day holiday service arrangements, with many outpatient services closed while emergency/inpatient/hemodialysis continue. Food safety alert (Macao): The Municipal Affairs Bureau ordered a recall after a black truffle sauce product was found to contain excess total arsenic; residents were urged to stop eating the affected batch. Local health services: Hong Kong’s Home Affairs Department opened temporary heat shelters with enhanced cooling, water access, and overnight bedding during very hot weather.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
